Circassia Group plc
Block Listing Interim Review
Oxford, UK - 1 April 2022: Circassia Group plc (LSE: CIR), a medical device company focused on point of care asthma diagnosis and management, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:
| Name of the company: | Circassia Group plc | |||
| Name of relevant scheme: | 1) Circassia EMI Share Option Scheme 2) Circassia 2007 Unapproved Share Scheme 3) Circassia 2014 Performance Share Plan Scheme 4) Circassia 2015 Performance Share Plan Scheme 5) Circassia 2016 Performance Share Plan Scheme 6) Circassia 2017 Performance Share Plan Scheme 7) Circassia 2020 Save As You Earn Scheme (UK) 8) Circassia 2020 Performance Share Plan Scheme 9) Circassia 2020 Deferred Share Bonus Plan | |||
| Period of return: | From: | 1 October 2021 | To: | 31 March 2022 |
| Balance of unallotted securities under scheme(s) from previous return: | 1) 700,750 2) 203,000 3) 76,676 4) 172,722 5) 580,926 6) 50,672 7) 1,126,893 8) 0 9) 0 Total 2,911,639 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 1) - 5) inclusive: Nil 6) 250,000 7) 0 8) 184,091 9) 823,467 | |||
| Less: Number of securities issued/allotted under scheme(s) during period:
| 1) - 5) inclusive: Nil 6) (12,050) 7) (61,335) 8) (184,091) 9) (823,467) Total (1,080,943) | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1) 700,750 2) 203,000 3) 76,676 4) 172,722 5) 580,926 6) 288,622 7) 1,065,558 8) 0 9) 0 Total 3,088,254 | |||
| Number and class of securities originally listed and the date of admission: | 1) 2,600,000 - 20 March 2014 2) 516,000 - 1 June 2017 3) 500,000 - 1 June 2017 4) 400,000 - 21 May 2018 5) 930,000 - 1 July 2019 6) 980,000 - 22 May 2020 6) 250,000 - 11 October 2021 7) 1,141,658 - 1 April 2021 8) 184,091 - 2 December 2021 9) 823,467 - 28 March 2022 | |||
| | | | | |
| Name of contact: | Sarah Duncan |
| Telephone number of contact: | 01865 405 560 |
For further information, please contact:
| Singer Capital Markets (Nominated Adviser and Broker) Aubrey Powell / Jen Boorer | Tel: +44 (0) 20 7496 3000 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.